Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

Although 70–80% of newly diagnosed ovarian cancer patients respond to first-line therapy, almost all relapse and five-year survival remains below 50%. One strategy to increase five-year survival is prolonging time to relapse by improving first-line therapy response. However, no biomarker today can a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shuford, Stephen, Wilhelm, Christine, Rayner, Melissa, Elrod, Ashley, Millard, Melissa, Mattingly, Christina, Lotstein, Alina, Smith, Ashley M., Guo, Qi Jin, O’Donnell, Lauren, Elder, Jeffrey, Puls, Larry, Weroha, S. John, Hou, Xiaonan, Zanfagnin, Valentina, Nick, Alpa, Stany, Michael P., Maxwell, G. Larry, Conrads, Thomas, Sood, Anil K., Orr, David, Holmes, Lillia M., Gevaert, Matthew, Crosswell, Howland E., DesRochers, Teresa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671958/
https://www.ncbi.nlm.nih.gov/pubmed/31371750
http://dx.doi.org/10.1038/s41598-019-47578-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6671958/
https://www.ncbi.nlm.nih.gov/pubmed/31371750
http://dx.doi.org/10.1038/s41598-019-47578-7

Ejemplares similares